脂质体紫杉醇在中晚期肺鳞癌维持治疗中的疗效观察

邵江河; 傅建伟; 王懿铭

doi:10.3971/j.issn.1000-8578.2018.17.1042

脂质体紫杉醇在中晚期肺鳞癌维持治疗中的疗效观察

Clinical Efficacy of Liposomal Paclitaxel in Maintenance Treatment of Patients with Advanced Squamous Cell Lung Carcinoma

摘要

摘要:
目的探讨以脂质体紫杉醇进行维持治疗对中晚期肺鳞癌患者的临床疗效及安全性。
方法 57例中晚期肺鳞癌患者完成4~6周期一线治疗后，被随机分为脂质体紫杉醇单药维持治疗组29例和随访观察组28例。观察治疗组患者的疗效及不良反应，比较两组无进展生存期（PFS）及总生存期（OS）。
结果脂质体紫杉醇单药维持治疗组的CR、PR、SD和PD分别为0、13.8%、44.8%和41.4%，疾病控制率（DCR）为58.6%，主要不良反应为骨髓抑制及胃肠道反应。两组患者中位PFS分别为5.7和2.4月，中位生存期（MST）分别为7.3和4.9月（均P < 0.05），脂质体紫杉醇治疗组的生活质量（QOL）优于观察组。
结论脂质体紫杉醇作为中晚期肺鳞癌一线治疗后的维持治疗，可显著改善治疗组患者PFS及OS，改善生活质量，不良反应可以耐受。

Abstract:
Objective To investigate the clinical efficacy and safety of liposome paclitaxel in maintenance therapy of advanced squamous cell lung carcinoma patients.
Methods After 4-6 cycles of first-line treatment, 57 patients with advanced squamous cell lung carcinoma were randomized into liposomal paclitaxel monotherapy maintenance treatment group(experimental group, n=29) and follow-up observation group(control group, n=28). Efficacy and side effects were observed in experimental group. PFS and OS were compared between two groups.
Results CR, PR, SD, PD rates of experimental group were 0, 13.8%, 44.8%, 41.4%, and disease control rate(DCR) was 58.6%. The major toxicities were myelosuppression and gastrointestinal reactions. PFS and median survival time(MST) of two groups were 5.7 vs. 2.4 months and 7.3 vs. 4.9 months(both P < 0.05). The patient's quality of life(QOL) was better in experimental group, compared with control group.
Conclusion As a maintenance therapy after the first-line treatment of advanced squamous cell lung carcinoma, liposomal paclitaxel could significantly improve PFS, OS and QOL of patients, and the adverse reactions are tolerable.

HTML全文

参考文献(14)

施引文献

资源附件(0)